SCHEMBL5031635

SCHEMBL5031635

Cc1ccc(C[C@@H](N)C(=O)N2C[C@H](CCCCNCCN)N(C(=O)[C@@H](N)Cc3ccc(C)cc3C)C[C@H]2CC(C)C)c(C)c1

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MC4R P32245 4/20 0.36
DPP4 P27487 4/20 0.35
FAP Q12884 4/20 0.35
DPP8 Q6V1X1 4/20 0.35
DPP9 Q86TI2 4/20 0.35
OPRM1 P35372 4/20 0.35
OPRD1 P41143 4/20 0.35
OPRK1 P41145 4/20 0.35
DPP7 Q9UHL4 3/20 0.35
FPR3 P25089 2/20 0.33
FPR2 P25090 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748573 1.00 MC4R (0.36) MC4RDPP4FAPDPP8DPP9
SCHEMBL1748571 1.00 MC4R (0.36) MC4RDPP4FAPDPP8DPP9
SCHEMBL1748929 0.97 MC4R (0.37) MC4RDPP4FAPDPP8DPP9
SCHEMBL1748928 0.97 MC4R (0.37) MC4RDPP4FAPDPP8DPP9
SCHEMBL2898430 0.91 DPP4 (0.40) MC4RDPP4FAPDPP8DPP9
SCHEMBL2898426 0.91 DPP4 (0.40) MC4RDPP4FAPDPP8DPP9
SCHEMBL2899175 0.91 MC4R (0.41) MC4RDPP4FAPDPP8DPP9
SCHEMBL14291345 0.91 MC4R (0.41) MC4RDPP4FAPDPP8DPP9
SCHEMBL14147557 0.91 DPP4 (0.40) MC4RDPP4FAPDPP8DPP9
SCHEMBL2899172 0.91 MC4R (0.41) MC4RDPP4FAPDPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1922072-A2 MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS Palatin Technologies, Inc. (US) 2008-05-21 EP claimed
WO-2007021990-A2 MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS PALATIN TECHNOLOGIES, INC. (US) 2007-02-22 WO claimed
US-20060287331-A1 MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS PALATIN TECHNOLOGIES, INC. (US) 2006-12-21 US claimed
EP-1922072-A2 MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS Palatin Technologies, Inc. (US) 2008-05-21 EP disclosed
WO-2007021990-A2 MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS PALATIN TECHNOLOGIES, INC. (US) 2007-02-22 WO disclosed
US-20060287331-A1 MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS PALATIN TECHNOLOGIES, INC. (US) 2006-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287331-A1 MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS MC4R, MC1R, MC5R MC4R 1/4885DPP4 820/4885FAP 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.